RééDOC
75 Boulevard Lobau
54042 NANCY cedex

Christelle Grandidier Documentaliste
03 83 52 67 64


F Nous contacter

0

Article

--";3! O
     

-A +A

Validation de la batterie rapide de dénomination (BARD) chez 382 temoins et 1004 patients d'une consultation memoire

CROISILE B; ASTIER JL; BEAUMONT A; MOLLION H
REV NEUROL (Paris) , 2010, vol. 166, n° 6-7, p. 584-593
Doc n°: 148491
Localisation : Documentation IRR

D.O.I. : http://dx.doi.org/DOI:10.1016/j.neurol.2010.01.017
Descripteurs : AD67 - MEMOIRE

The Rapid BAttery of Denomination (BARD) is a short 10-item naming
test derived from the 60-item Boston Naming Test. It is easily performed in less
than 15 seconds by normal controls independently of age, gender and education
(Croisile, 2005,2007,2008). Our aim was to evaluate the BARD in various
conditions seen in a memory clinic. The BARD was used in
382 normal subjects (165 men and 217 women, aged from 20 to 97 years) and 1004
patients attending a memory clinic. Three groups of 505 patients with Alzheimer's
disease (AD) were compared: mild patients (n=402), moderate patients (n=84) and
moderately severe patients (n=19). The BARD was also used in 499 patients with a
Mini Mental Status (MMSE)>or=20: 173 patients with amnestic Mild Cognitive
Impairment (aMCI), 56 patients with frontotemporal dementia (FTD), 41 patients
with Lewy Body dementia (LBD), 36 patients with nonfluent primary progressive
aphasia (NFPPA), 27 patients with semantic dementia (SD), 16 patients with
posterior cortical atrophy (PCA), 150 patients with anxiety or depression (ADD).
RESULTS: The performance of the patients was not affected by age, gender or
education. aMCI had a score of 9.97+/-0.18, ADD a score of 9.97+/-0.2. A mild
anomia was observed in three groups: mild AD (9.78+/-0.5), FTD (9.79+/-0.65) et
LBD (9.98+/-0.16). A more pronounced anomia was present in moderate AD
(9.10+/-1.06), moderately severe AD (8.05+/-1.27), PCA (8.12+/-3.28) and NFPPA
(8.44+/-1.61). The anomia was severe in SD (5.85+/-2.46). The 10 items were
perfectly named by 98 % of ADD, 96.53 % of aMCI, 82.09 % of mild AD, 87.5 % of
FTD patients, 97.56 % of LBD patients, 68.75 % of PCA patients, but only 45.24 %
moderate AD, 5.26 % of moderately severe AD, 27.78 % of NFPPA, and 3.7 % of SD.
In the patients with MMS>or=20, Anova showed that the BARD scores of the ADD,
aMCI, mild AD, FTD and LBD groups were significantly greater than the BARD scores
of NFPPA, SD and PCA. PCA and NFPPA groups did not differ for BARD scores whereas
they were significantly better than SD. A ROC curve comparing the 822 mild anomic
patients (AD, FTD, LBD, aMCI, ADD) with the 79 more anomic patients (NFPPA, SD,
PCA) showed that for a BARD score of 10, sensitivity was 72.2 %, specificity was
89.2 %, and 87.7 % of the patients were correctly classified. CONCLUSION: The
BARD is a quick and useful tool for identifying naming disorders in a memory
clinic. In patients with MMSE>or=20, making one error at the BARD is highly
abnormal and significantly characteristic of cognitive disorders: the more
frequent the errors are, the more probable is the presence of a visual agnosia
(PCA), an aphasia (NFPPA), or a semantic disorder (SD).

Langue : FRANCAIS

Mes paniers

4

Gerer mes paniers

0